Literature DB >> 12441171

XIB4035, a novel nonpeptidyl small molecule agonist for GFRalpha-1.

Kimiko Tokugawa1, Kyoko Yamamoto, Mariko Nishiguchi, Takumi Sekine, Masahiko Sakai, Tomokazu Ueki, Shigeyuki Chaki, Shigeru Okuyama.   

Abstract

We investigated the agonistic activities of N(4)-(7-chloro-2-[(E)-2-(2-chloro-phenyl)-vinyl]-quinolin-4-yl)-N(1),N(1)-diethyl-pentane-1,4-diamine (XIB4035), at the glial cell line-derived neurotrophic factor (GDNF) family receptoralpha-1(GFRalpha-1) in Neuro-2A cells, a mouse neuroblastoma cell line which is a suitable model for investigating functions mediated through GFRalpha-1. XIB4035 concentration-dependently inhibited [(125)I]GDNF binding in Neuro-2A cells with an IC(50) of 10.4 microM. GDNF induced autophosphorylation of Ret protein, and promoted neurite outgrowth in Neuro-2A cells. XIB4035, like GDNF, induced Ret autophosphorylation in the Neuro-2A cells. Moreover, XIB4035 promoted neurite outgrowth in a concentration-dependent manner. These results show that XIB4035 may act as an agonist at GFRalpha-1 receptor complex, and mimic neurotrophic effects of GDNF in Neuro-2A cells. This is an interesting finding showing that a nonpeptidyl small molecule is capable of inducing activation of a receptor that normally bind a relatively large protein ligand such as GDNF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12441171     DOI: 10.1016/s0197-0186(02)00053-0

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  16 in total

1.  Augmenting glial cell-line derived neurotrophic factor signaling to treat painful neuropathies.

Authors:  Ahmet Höke
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-28       Impact factor: 11.205

2.  Treating small fiber neuropathy by topical application of a small molecule modulator of ligand-induced GFRα/RET receptor signaling.

Authors:  Kristian L Hedstrom; Joshua C Murtie; Kathryn Albers; Nigel A Calcutt; Gabriel Corfas
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-21       Impact factor: 11.205

3.  Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo.

Authors:  Tobias Gyárfás; Juha Knuuttila; Päivi Lindholm; Tomi Rantamäki; Eero Castrén
Journal:  Cell Mol Neurobiol       Date:  2009-09-24       Impact factor: 5.046

Review 4.  GDNF--a potential target to treat addiction.

Authors:  Sebastien Carnicella; Dorit Ron
Journal:  Pharmacol Ther       Date:  2008-12-24       Impact factor: 12.310

Review 5.  Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration.

Authors:  Khalid Bashir Dar; Aashiq Hussain Bhat; Shajrul Amin; Bilal Ahmad Reshi; Mohammad Afzal Zargar; Akbar Masood; Showkat Ahmad Ganie
Journal:  Cell Mol Neurobiol       Date:  2019-10-04       Impact factor: 5.046

Review 6.  Treatment of Parkinson's disease with trophic factors.

Authors:  Amie L Peterson; John G Nutt
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

7.  Ret is essential to mediate GDNF's neuroprotective and neuroregenerative effect in a Parkinson disease mouse model.

Authors:  Anja Drinkut; Karsten Tillack; Durga P Meka; Jorg B Schulz; Sebastian Kügler; Edgar R Kramer
Journal:  Cell Death Dis       Date:  2016-09-08       Impact factor: 8.469

8.  A Novel Small Molecule GDNF Receptor RET Agonist, BT13, Promotes Neurite Growth from Sensory Neurons in Vitro and Attenuates Experimental Neuropathy in the Rat.

Authors:  Yulia A Sidorova; Maxim M Bespalov; Agnes W Wong; Oleg Kambur; Viljami Jokinen; Tuomas O Lilius; Ilida Suleymanova; Gunnar Karelson; Pekka V Rauhala; Mati Karelson; Peregrine B Osborne; Janet R Keast; Eija A Kalso; Mart Saarma
Journal:  Front Pharmacol       Date:  2017-06-21       Impact factor: 5.810

9.  Small-Molecule Ligands as Potential GDNF Family Receptor Agonists.

Authors:  Larisa Ivanova; Jaana Tammiku-Taul; Yulia Sidorova; Mart Saarma; Mati Karelson
Journal:  ACS Omega       Date:  2018-01-25

10.  Novel RET agonist for the treatment of experimental neuropathies.

Authors:  Hanna Viisanen; Ulpukka Nuotio; Oleg Kambur; Arun Kumar Mahato; Viljami Jokinen; Tuomas Lilius; Wei Li; Hélder A Santos; Mati Karelson; Pekka Rauhala; Eija Kalso; Yulia A Sidorova
Journal:  Mol Pain       Date:  2020 Jan-Dec       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.